This panel covers 513 genes for DNA analysis and 49 genes for RNA (fusion) detection.
It identifies cancer signatures by analysing key parameters such as SNV, CNV, TMB, MSI and HRD.
A major advantage is that it needs a minimal sample of only 10 ng and offers sensitivity above 99.5% and specificity above 97.6%.
• Single-gene biomarkers
Detects single nucleotide variants (SNV), insertions and deletions, known and novel fusions, and copy number variants (CNV).
• Multi-gene biomarkers
Tumor mutational burden (TMB) and microsatellite instability (MSI) scoring determine the tendency to mutation, enabling the analysis of mutational signatures and the assessment of potential response to immunotherapies.
• Simultaneous analysis of 49 fusion genes
Directly detects 1,311 known fusion isoforms as well as novel, previously unknown fusion isoforms.
• Homologous recombination deficiency (HRD)
Determines genomic instability by detecting loss of heterozygosity (LOH) at gene and sample level in 46 key genes of the homologous recombination repair pathways.
• Works with low sample amounts
10 ng or more of tissue-derived DNA/RNA is sufficient for analysis, so more analyses can be run from a smaller amount of tissue than with conventional tests.
• High test success
High sequencing success rates (up to 95%) allow more samples to be tested without problems.
• Highly automated workflow
An automated, short processing protocol increases laboratory efficiency and reduces potential user errors.
Benefits
• Targeted therapy
• Personalized treatment
• Smart drugs / immunotherapy
• The chance to avoid potential side effects of chemotherapy